These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25500884)

  • 1. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.
    Bailey JR; Wasilewski LN; Snider AE; El-Diwany R; Osburn WO; Keck Z; Foung SK; Ray SC
    J Clin Invest; 2015 Jan; 125(1):437-47. PubMed ID: 25500884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
    Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
    Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Breadth of Hepatitis C Virus Neutralization.
    Kinchen VJ; Bailey JR
    Front Immunol; 2018; 9():1703. PubMed ID: 30116237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.
    Wasilewski LN; El-Diwany R; Munshaw S; Snider AE; Brady JK; Osburn WO; Ray SC; Bailey JR
    J Virol; 2016 Jan; 90(7):3773-82. PubMed ID: 26819308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.
    Gal-Tanamy M; Keck ZY; Yi M; McKeating JA; Patel AH; Foung SK; Lemon SM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19450-5. PubMed ID: 19052239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
    Mankowski MC; Kinchen VJ; Wasilewski LN; Flyak AI; Ray SC; Crowe JE; Bailey JR
    Proc Natl Acad Sci U S A; 2018 Jan; 115(1):E82-E91. PubMed ID: 29255018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
    Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
    Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
    J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.